Efficacy and safety of Rilpivirine for anti-human immunodeficiency virus conversion therapy

doi:10.3969/j.issn.1672-3384.2021.03.005

PDF(594 KB)

Clinical Medication Journal ›› 2021, Vol. 19 ›› Issue (3) : 26-30. DOI: 10.3969/j.issn.1672-3384.2021.03.005

Drug Therapy of Acquired Immunodeficiency Syndrome

Efficacy and safety of Rilpivirine for anti-human immunodeficiency virus conversion therapy

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2021, 19(3): 26-30 https://doi.org/10.3969/j.issn.1672-3384.2021.03.005

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(594 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2020-11-30	2021-03-11
Issue Date
2021-03-11

Please choose a citation manager

Content to export